Neutropenia clinical trials
The registry lists 316 studies for Neutropenia across more than 10 countries. 42 are recruiting or about to start. 109 of them are mainly about Neutropenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Febrile Neutropenia too: 429 studies, 72 open.
Get an email when these change. Save the Neutropenia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Amgen (14) · National Heart, Lung, and Blood Institute (NHLBI) (13) · Pfizer (9) · National Cancer Institute (NCI) (8) · EVIVE Biotechnology (7) · Sandoz (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Tianjin SinoBiotech Ltd. (4)
What is being tested here
Drugs under test in Neutropenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Filgrastim | 1 | 5 | 20 |
| Letermovir | 1 | 0 | 3 |
| Pegylated granulocyte colony-stimulating factor | 1 | 0 | 3 |
| Levofloxacin | 1 | 2 | 3 |
| Mavorixafor | 1 | 1 | 2 |
| Bevacizumab | 1 | 0 | 1 |
| Trilaciclib | 1 | 0 | 1 |
| PM 01183 | 1 | 0 | 1 |
| Eravacycline | 1 | 0 | 1 |
| Luspatercept | 1 | 0 | 1 |
Drug classes tested here Antimetabolites 1 open · Beta-lactamase inhibitors 1 open · Antimitotic agents 7 · Alkylating agents 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Sep 2027A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections · Phase 3 · X4 Pharmaceuticals
- Dec 2026Study of Trilaciclib and Lurbinectidin · UNC Lineberger Comprehensive Cancer Center
- Dec 2026Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection · Hebei Medical University Fourth Hospital
- Dec 2026Prevalence of Ethnic Neutropenia and Duffy Null Phenotype in Neonates · Kaplan Medical Center
- Feb 2027Luspatercept for Clonal Cytopenias of Uncertain Significance · Weill Medical College of Cornell University
- Feb 2027Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- Mar 2027Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers · Alexandria University
- Mar 2027G-CSF In Neonatal Sepsis With Neutropenia · University of Health Sciences Lahore
- Apr 2027Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Apr 2027A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers · BioGeneric Pharma
Who these studies take
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger. 11 (46%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (4%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 9 (38%) | 9 (38%) |
| 18 | 20 (83%) | 20 (83%) |
| 30 | 16 (67%) | 16 (67%) |
| 40 | 16 (67%) | 16 (67%) |
| 50 | 16 (67%) | 16 (67%) |
| 65 | 16 (67%) | 16 (67%) |
| 75 | 14 (58%) | 14 (58%) |
| 85 | 12 (50%) | 12 (50%) |
Across all 316 studies, recruiting or not: 38% stop at 75 or younger and 24% at 65; 34% take children; 12% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Neutropenia studies take
Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 29 mo11–41 · 25 studies | — | — |
| Phase 3 | 20 mo11–34 · 16 studies | — | — |
| Interventional, no phase | 31 mo26–40 · 14 studies | — | — |
| Observational | 43 mo18–190 · 23 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- Swiss 2024 Continous Fever Monitoring in Pediatric Oncology PatientsOct 22, 2026NCT05940766
Newly registered5
- Time Course of Clozapine-associated Agranulocytosis Over 19 YearsNov 3, 2026NCT07913529
- Diagnostic Accuracy, Clinical Utility and Implementation of Point-of-Care Absolute Neutrophil Count in Suspected Neutropenic Fever (DUCATIS) - Diagnostic Accuracy (S1)Oct 28, 2026NCT07901660
- G-CSF In Neonatal Sepsis With NeutropeniaOct 22, 2026NCT07888829
- A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy VolunteersOct 16, 2026NCT07877467
- Effects of Resistance Training on Recovery During Hematopoietic Stem Cell TransplantationOct 14, 2026NCT07872813
Studies
Recruiting first, then most recently updated. Showing 50 of 316. Browse all 316 → or search them.
- Screening for Hematology Branch ProtocolsEnrolling by invitationNCT000016201 country
- A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersNot yet recruitingNCT07902830Phase 2
- Diagnostic Accuracy, Clinical Utility and Implementation of Point-of-Care Absolute Neutrophil Count in Suspected Neutropenic Fever (DUCATIS) - Diagnostic Accuracy (S1)Not yet recruitingNCT07901660Not applicable1 country
- Swiss 2024 Continous Fever Monitoring in Pediatric Oncology PatientsRecruitingNCT05940766Not applicable1 country
- G-CSF In Neonatal Sepsis With NeutropeniaNot yet recruitingNCT07888829Not applicable1 country
- A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy VolunteersNot yet recruitingNCT07877467Phase 1
- Effects of Resistance Training on Recovery During Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07872813Not applicable1 country
- the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast CancerRecruitingNCT07380646Phase 21 country
- Study of Trilaciclib and LurbinectidinRecruitingNCT05578326Phase 21 country
- Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant EnterobacteriaceaeNot yet recruitingNCT073965711 country
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruitingNCT077630541 country
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsRecruitingNCT06056297Phase 325 countries
- Phase II Study of QLC2519 in Pediatric Solid Tumor ParticipantsRecruitingNCT07724756Phase 21 country
- Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic ChildrenRecruitingNCT077252631 country
- Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)Not yet recruitingNCT07528417Phase 21 country
- Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood CancersRecruitingNCT07300735Not applicable1 country
- Early Discontinuation of Antibiotics in Paediatric High-risk Febrile NeutropeniaNot yet recruitingNCT07590648Phase 41 country
- Letermovir vs Valganciclovir in CMV R+ Kidney TransplantNot yet recruitingNCT07571135Phase 41 country
- Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid TumorsRecruitingNCT06926751Phase 21 country
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaRecruitingNCT05537896Phase 21 country
- Shwachman Diamond Syndrome Registry and StudyRecruitingNCT060569081 country
- Luspatercept for Clonal Cytopenias of Uncertain SignificanceRecruitingNCT06788691Phase 21 country
- Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim InjectionRecruitingNCT074340631 country
- Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor ChemoradiotherapyRecruitingNCT07205536Phase 21 country
- Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid TumorRecruitingNCT070964791 country
- BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC PatientsNot yet recruitingNCT07071844Phase 21 country
- Serial Blood Count StudyRecruitingNCT07066085Early Phase 11 country
- Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)Not yet recruitingNCT07047352Not applicable1 country
- A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma PatientsNot yet recruitingNCT07018271Not applicable
- Breath Analysis for the Detection of Invasive Fungal InfectionsRecruitingNCT065377261 country
- The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel DiseaseRecruitingNCT069139981 country
- Prevalence of Ethnic Neutropenia and Duffy Null Phenotype in NeonatesRecruitingNCT069086161 country
- UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaRecruitingNCT06245746Phase 11 country
- Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug MonitoringNot yet recruitingNCT06749041
- A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.Not yet recruitingNCT06649448Not applicable1 country
- Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of EpilepsyNot yet recruitingNCT06491303
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological PatientsRecruitingNCT06422533Not applicable1 country
- A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBCNot yet recruitingNCT063609521 country
- Hematological Effects of Atypical Antipsychotics (AAPs) in a Geriatric Population: What is the Role of 5-HT2 ReceptorsRecruitingNCT061073221 country
- Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & NeutropeniaRecruitingNCT025365991 country
- Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.Not yet recruitingNCT05852249
- Cologne Cohort of Neutropenic Patients (CoCoNut)RecruitingNCT018214561 country
- Time Course of Clozapine-associated Agranulocytosis Over 19 YearsCompletedNCT079135291 country
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant RecipientsCompletedNCT05626530Phase 41 country
- Mucorales PCR Screening in At-risk Hematology PatientsCompletedNCT05925660Not applicable1 country
- Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile NeutropeniaCompletedNCT05926063Phase 41 country
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMSCompletedNCT00967785Phase 1/21 country
- RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed AdultsActive, not recruitingNCT07816471
- Metagenomic Sequencing for the Identification of Pathogens in Febrile Neutropenic PatientsTerminatedNCT06075888Not applicable1 country
- Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant DiseasesCompletedNCT07671508Phase 2/3